He's 11-years-old and, until he can receive his shots, Gronvall's been using at-home COVID-19 test kits in order to determine if his sniffles are more than allergies or a slight cold. The test swabs are longer than a Q-tip, but easier on the nasal cavity than a flu diagnostic or the original "brain swab" used to test for COVID since early in the pandemic. "There's often a lot of stuff coming out of their nose," Gronvall said of her kids, with a slight chuckle, when we talked recently. As an associate professor at the Johns Hopkins Bloomberg School of Public Health, Gronvall knows the importance of testing. "We can't all rely on everybody being extra scrupulous and paying attention to all of the COVID restrictions," she said.

New coronavirus tests are being developed every day. The Trump administration just ordered 150 million rapid antigen tests from Abbott Laboratories, but how do they stack up against other tests like the Polymerase chain reaction (PCR) test? Top infectious disease doctors from Harvard and Johns Hopkins break down the differences between the two tests to determine which diagnostic tool might be better at curbing transmission rates. Rapid antigen tests could play a pivotal role in curbing the spread of the coronavirus, according to some of the country's top medical professionals. Antigen tests are the type of tests the White House just ordered from Abbott Laboratories in a $750 million deal that will reportedly buy 150 million of its new rapid coronavirus tests: the BinaxNOW COVID-19 Ag Card.